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Objectives: Severe acute pancreatitis (SAP) has high morbidity and mortality but there are no widely
accepted predictive biomarkers in clinical use. Matrix metalloproteinases (MMPs) are active in tissue
destruction and inflammatory responses. We studied whether serum levels of activated MMP-8 (aMMP-
8), MMP-9 and their regulators tissue inhibitor of matrix metalloproteinases (TIMP)-1, myeloperoxidase
(MPO) and human neutrophil elastase (HNE) could predict the development of SAP.
Methods: The study comprised 214 AP patients (revised Atlanta classification: 142 mild, MAP; 54
moderately severe, MSAP; 18 SAP) referred to Helsinki University Hospital. A venous blood sample was
taken within 72 h from the onset of symptoms. Serum levels of aMMP-8 were determined using
immunofluorometric assay, and those of MMP-9, TIMP-1, MPO and HNE using enzyme-linked immu-
nosorbent assay. AP groups were compared using Jonckheere-Terpstra test and predictive value for SAP
was analyzed using receiver operating characteristics (ROC) analysis.
Results: Serum aMMP-8 levels were higher in SAP (median 657 ng/ml, interquartile range 542e738 ng/
ml) compared to MSAP (358 ng/ml, 175e564 ng/ml; p < 0.001) and MAP (231 ng/ml, 128e507 ng/ml;
p < 0.001). Similar trend was seen with TIMP-1 and MPO. In ROC analysis aMMP-8, MPO and TIMP-1
emerged as potential markers for the development of SAP (areas under ROC curves 0.83, 0.71 and
0.69, respectively).
Conclusions: Serum aMMP-8 measured early in the course of AP (within 72 h of symptom onset) pre-
dicted the development of SAP.
© 2021 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Acute pancreatitis (AP) is classified as mild, moderately severe
or severe according to the revised Atlanta classification [1]. AP is
common and increasing in many parts of Europe [2]. While the
disease is often mild and associated with rapid recovery, patients
developing persisting organ dysfunction (OD) and thus, severe AP,
have high morbidity and mortality up to 52% [3]. Ability to predict
the course of disease in AP patients would help in guiding treat-
ment decisions and using intensive care unit (ICU) resources.PO Box 340, 00029, HUS,
.
B.V. on behalf of IAP and EPC. ThisCurrent clinical scoring systems, such as acute physiology and
chronic health evaluation (APACHE) II and sequential organ failure
assessment (SOFA), have limited value in predicting disease
severity [4].
Although several biomarkers have been proposed to predict AP
severity at the early phases of the disease [5e7], there are currently
no widely accepted biomarkers in clinical practice. Matrix metal-
loproteinases (MMPs) are a group of proteolytic enzymes respon-
sible for soft and hard tissue degradation [8]. MMP-8 also plays a
part in acute inflammation and affects the migration of leukocytes
[9]. Plasma MMP-8 and MMP-9 levels have been shown to be
higher in severe AP compared to mild AP [10]. Determining the
activated form of MMP-8 (aMMP-8) in saliva is a useable means to
detect periodontal inflammation in clinical practice, for which a
bedside test has been developed [11].is an open access article under the CC BY-NC-ND license (http://creativecommons.
Fig. 1. Flow chart of patient selection and outcome. AP ¼ acute pancreatitis, OD ¼ organ dysfunction.
Table 1
Characteristics of the patients.
Severity of acute pancreatitis Mild (n ¼ 142; 66%) Moderately severe (n ¼ 54; 25%) Severe (n ¼ 18; 8%)
Male sex, n (%) 93 (66%) 37 (69%) 15 (83%)
Age (yr) 51.1 (20e89) 52.7 (24e86) 50.6 (25e81)
Etiology of AP, n (%)
Alcohol 73 (51%) 33 (61%) 13 (72%)
Biliary 36 (25%) 11 (20%) 3 (17%)
Post-ERCP 2 (1%) 3 (6%) 0 (0%)
Idiopathic 22 (16%) 6 (11%) 1 (6%)
Other 9 (6%) 1 (2%) 1 (6%)
Hospital length of stay (d) 4.5 (1e15) 9.8 (2e24) 33.6 (4e94)
ICU admission, n (%) 0 (0%) 5 (9%) 17 (94%)
ICU length of stay (d) NA 3.8 (2e6) 18.7 (2e55)
Plasma C-reactive protein on admission (mg/l) 36.0 (3e252) 26.4 (3e256) 56.8 (3e466)
Plasma C-reactive protein at sampling (mg/l) 79.0 (3e400) 92.0 (3e333) 152.4 (5e495)
Plasma creatinine on admission (mmol/l) 73.5 (32e409) 73.9 (32e172) 105.6 (57e295)
Plasma creatinine at sampling (mmol/l) 68.4 (31e597) 64.9 (31e158) 126.2 (52e292)
30-day mortality, n (%) 0 (0%) 0 (0%) 8 (44%)
SOFA score on admission 0.9 (0e5) 1.5 (0e6) 3.6 (0e9)
SOFA score at sampling 1.2 (0e6) 2.1 (0e6) 4.8 (1e9)
APACHEII score on admission 5.2 (0e15) 6.3 (0e16) 8.0 (2e15)
APACHEII score at sampling 4.9 (0e16) 6.9 (1e15) 9.2 (1e15)
MMS on admission 0.2 (0e3) 0.4 (0e2) 0.7 (0e3)
MMS at sampling 0.4 (0e4) 0.8 (0e3) 1.7 (0e5)
Time from onset to admission (h) 20.1 (1e48) 15.8 (2e48) 21.2 (3e48)
Time from onset to sampling (h) 36.6 (4e71) 32.1 (9e74) 35.3 (9e72)
Time from admission to sampling (h) 16.3 (1e42) 16.3 (4e48) 14.1 (1e31)
First AP, n (%) 109 (77%) 38 (70%) 16 (89%)
Local complication, n (%) 0 (0%) 30 (56%) 13 (72%)
Pancreatic necrosis, n (%) 0 (0%) 20 (37%) 15 (83%)
CT, n (%) 78 (55%) 45 (83%) 17 (94%)
MRI, n (%) 41 (29%) 11 (20%) 1 (6%)
Necrosectomy, n (%) 0 (0%) 0 (0%) 5 (28%)
Open abdomen, n (%) 0 (0%) 0 (0%) 3 (17%)
Secondary infection, n (%) 12 (9%) 16 (30%) 15 (83%)
Pneumonia 3 (25%) 8 (50%) 4 (27%)
Urinary tract infection 3 (25%) 4 (25%) 0 (0%)
(continued on next page)
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Table 1 (continued )
Severity of acute pancreatitis Mild (n ¼ 142; 66%) Moderately severe (n ¼ 54; 25%) Severe (n ¼ 18; 8%)
Cholecystitis 4 (33%) 1 (6%) 0 (0%)
Intra-abdominal infection 0 (0%) 0 (0%) 9 (60%)
Other 2 (17%) 3 (19%) 2 (13%)
Bacteremia 1 (1%) 3 (6%) 5 (28%)
Data shown as mean (minimum-maximum) or number of patients (percentage). AP ¼ acute pancreatitis; ICU ¼ intensive care unit; SOFA ¼ sequential organ failure
assessment; APACHEII¼ acute physiology and chronic health evaluation II; MMS¼ModifiedMarshall score; CT¼ computed tomography; MRI¼magnetic resonance imaging.
A. Turunen, K. Kuuliala, A. Kuuliala et al. Pancreatology 21 (2021) 862e869The activation of MMPs is tightly regulated. Tissue inhibitors of
matrix metalloproteinases (TIMPs) such as TIMP-1 can down-
regulate the activation of MMP-8 [12]. Myeloperoxidase (MPO)
and human neutrophil elastase (HNE) are released upon neutrophil
degranulation, and they both activate oxidatively and proteolyti-
cally MMP-8 and MMP-9 and inhibit TIMP-1 [13], respectively.Fig. 2. Serum a) activated matrix metalloprotease (MMP)-8 concentration, b) MMP-9 con
aMMP-8/TIMP-1 ratio, e) molar MMP-9/TIMP-1 ratio, and f) myeloperoxidase (MPO) conce
Individual measurements are shown overlaid with horizontal lines denoting medians and b
Terpstra test, with statistically significant post hoc p-values comparing groups shown.
864To the best of our knowledge, aMMP-8 levels have not been
studied in AP. We have shown that total MMP-8 levels takenwithin
96 h from the onset of AP symptoms can predict the development
of persistent OD [10]. The aim of this studywas to examinewhether
levels of aMMP-8 along with MMP-9, TIMP-1, MPO and HNE could
predict the severity of AP at earlier stages of the disease.centration, c) tissue inhibitor of metalloproteinases (TIMP)-1 concentration, d) molar
ntration according to the severity of acute pancreatitis (revised Atlanta classification).
oxes denoting 25th to 75th percentiles. The groups were compared using Jonckheere-
Fig. 3. Receiver operating characteristic (ROC) curves for predicting severe acute
pancreatitis among a) all patients, b) patients with no OD at sampling, and c) patients
with OD at sampling.
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Patients
Patient recruitment took place in Helsinki University Hospital
from December 2013 to May 2019. Inclusion criteria were: AP
diagnosed according to the revised Atlanta Classification (epigastric
pain typical to AP and elevation of plasma amylase levels at least
three times the normal upper limit and/or typical findings in
computed tomography [CT]) [1],48 h from the onset of symptoms
and nomore than two previous diagnosed AP attacks. Patients with
chronic pancreatitis, knownmalignancy or age under 18 years were
excluded from the study.
The presence of organ dysfunction (OD) was assessed according
to the Modified Marshall Score (MMS), in which three organ sys-
tems (respiratory, cardiovascular and renal) are evaluated and OD is
present if the patient receives at least two points from at least one
of the organ systems [14]. The severity of AP was retrospectively
classified as mild (MAP), moderately severe (MSAP), or severe (SAP)
according to the revised Atlanta classification [1], where MSAP is
defined by transient OD resolving within 48 h, systemic compli-
cations or exacerbation of co-morbid disease, and SAP by persistent
OD lasting over 48 h.
Written informed consent was acquired from all the 255
recruited patients or their next of kin. The final study comprised of
214 patients. Patient groups are shown in Fig. 1.Serum biomarkers
A serum sample was obtained within 72 h from onset of
symptoms and kept frozen at 80 C.
Activated MMP-8 concentration was measured using an
immunofluorometric assay (IFMA), as described previously [15].
Briefly, the monoclonal MMP-8 specific antibodies 8708 and 8706
(Oy Medix Biochemica Ab, Espoo, Finland) were used in IFMA as a
catching antibody and a tracer antibody, respectively. The tracer
antibody was labeled using europium-chelate [16]. The assay buffer
contained 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 50 mM
ZnCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/l diethylene-
triaminepentaacetic acid. Samples were diluted in assay buffer and
incubated for 1 h, followed by incubation for 1 h with tracer anti-
body. Enhancement solution was added and after 5 min fluores-
cence was measured using EnVision 2105 Multimode Plate Reader
(PerkinElmer Finland, Turku, Finland). The detection limit for the
assay is 0.08 ng/ml. The time to result is 3e4 h.
Commercially available enzyme-linked immunosorbent assay
(ELISA) kits were used for measurement of MMP-9 (R&D Systems,
Minneapolis, MN, USA), TIMP-1 (Amersham Biosciences, GE
Healthcare, Buckinghamshire, UK), MPO (Immundiagnostik AG,
Bensheim, Germany), and HNE (Invitrogen, Thermo Fisher Scien-
tific, Waltham, MA, USA) according to the manufacturers’ in-
structions. Briefly, prepared serially diluted standards and samples
were added to each pre-coated well of microplate according to the
kit protocols. After incubation on a plate shaker at room tempera-
ture, the wells were washed to remove unbound material, and
conjugated secondary antibodies were added and again incubated
on a plate shaker. As substrate tetramethylbenzidine is used in
these kits, the detection of color signal was carried out by
measuring the absorbance at 450 nm using Victor™ X4 (Wallac Oy,
Turku, Finland by PerkinElmer, Singapore) with a detection limit of
MMP-9, TIMP-1, MPO, and HNE 0,6 ng/ml, 0,3 ng/ml, and 1.98 pg/
ml, respectively. The time to result is approximately 4 h.
Table 2
Ability of markers to predict severe acute pancreatitis among all patients, in patients without OD at sampling, or those patients with OD at sampling (n¼ 15). The optimum cut-
off level was determined using the Youden method.
Variable ROC AUC (95% CI) Cut-off Sensitivity (95% CI) Specificity (95% CI) LRþ (95% CI)
All patients aMMP-8 0.83 (0.72e0.93) 600.5 ng/ml 72% (47%e90%) 87% (82%e92%) 5.66 (3.56e9.01)
MPO 0.71 (0.57e0.86) 705.6 ng/ml 72% (47%e90%) 77% (70%e82%) 3.08 (2.10e4.51)
TIMP-1 0.69 (0.53e0.85) 295.7 ng/ml 56% (31%e79%) 84% (78%e89%) 3.40 (2.02e5.73)
Patients without OD at sampling aMMP-8 0.78 (0.63e0.92) 639.5 ng/ml 58% (28%e85%) 90% (85%e94%) 5.74 (3.03e10.89)
MPO 0.68 (0.50e0.85) 705.6 ng/ml 67% (35%e90%) 78% (71%e83%) 2.97 (1.84e4.80)
aMMP-8/TIMP-1 0.67 (0.56e0.78) 0.546 100% (74%e100%) 43% (36%e50%) 1.75 (1.54e1.98)
Patients with OD at sampling aMMP-8 0.92 (0.79e1.00) 499.9 ng/ml 100% (54%e100%) 78% (40%e97%) 4.50 (1.33e15.28)
TIMP-1 0.91 (0.76e1.00) 411.1 ng/ml 100% (54%e100%) 78% (40%e97%) 4.50 (1.33e15.28)
MMP-9/TIMP-1 0.11 (0.00e0.28) 1.32a 100% (54%e100%) 78% (40%e97%) 4.50 (1.33e15.28)
a Lower values predict severe AP. ROC AUC ¼ area under receiver operating characteristic curve, CI ¼ confidence interval, LRþ ¼ positive likelihood ratio, aMMP-
8 ¼ activated matrix metalloproteinase-8, TIMP-1 ¼ tissue inhibitor of metalloproteinases-1.
A. Turunen, K. Kuuliala, A. Kuuliala et al. Pancreatology 21 (2021) 862e869Statistics
The results are shown as means with ranges, medians with
interquartile ranges, or numbers of patients with percentages.
Variables were compared among AP severity groups using
Jonckheere-Terpstra test with post hoc Mann-Whitney test, and
among AP etiology groups using Kruskal-Wallis test with post hoc
Mann-Whitney test and by multinomial logistic regression.
Receiver operating characteristic (ROC) analysis was used for
determining the ability of variables to predict severe AP, and the
area under the curve was calculated with 95% confidence intervals
(CI). The optimal cut-off values were determined using the Youden
method, and corresponding sensitivity, specificity, and the positive
likelihood ratios were calculated with 95% CI. No adjustment was
made for multiple testing. Statistical analysis was performed using
SPSS version 25 (IBM, Chicago, IL, USA).Results
Clinical and demographic features of the patients are shown in
Table 1. The association of the severity of acute pancreatitis with
serum levels of aMMP-8, MMP-9, TIMP-1, and MPO is shown in
Fig. 2. The levels of HNE were below detection limit in most sam-
ples and were not statistically analyzed further.
Serum aMMP-8, TIMP-1, and MPO levels were higher in severe
acute pancreatitis (SAP) than in mild (MAP) or moderately severe
disease (MSAP) (Fig. 2; A, C, and F). Accordingly, in ROC analysis
these markers predicted SAP (Fig. 3A), with the associated areas
under curve, optimal cut-off values, sensitivities, specificities, and
positive likelihood ratios shown in Table 2.
The majority of the patients (n ¼ 199) had no signs of organ
dysfunction (OD) at sampling. SAP eventually occurred in 12 of
these patients, predicted in ROC analysis by aMMP-8 and MPO
levels, as well as aMMP-8/TIMP-1 molar ratio (Fig. 3b, Table 2).
Some patients (n ¼ 17) had OD already at sampling. We studied
if the examined molecules could predict whether the OD would
persist (SAP; n ¼ 6) or be transient (subsiding within 48 h; n ¼ 9).
Serum aMMP-8 and TIMP-1 concentrations, as well as MMP-9/
TIMP-1 molar ratio predicted persistent OD (Fig. 3c; Table 2).
In secondary statistical analysis it was found that serum TIMP-1
levels were higher in acute pancreatitis caused by biliary obstruc-
tion, compared to those caused by alcohol use or other factors, or
deemed idiopathic (Fig. 4A). Accordingly, the molar ratios with
aMMP-8 and MMP-9 were lower in biliary AP (Fig. 4B and C). No
difference was found while comparing the other markers studied
according to etiology of AP (data not shown). In multinomial lo-
gistic regression analysis (Table 3), the differences in TIMP-1 levels
between biliary AP and AP due to other etiologies remained sta-
tistically significant even after adjustment for age, sex, and severity866of AP.Discussion
The results reveal that the serum levels of activated MMP-8
(aMMP-8), as determined early in the course of acute pancreatitis
(AP) (<72 h from the onset of symptoms), predict severe AP (SAP).
MMP-activating myeloperoxidase (MPO) and MMP-inhibiting tis-
sue inhibitor of metalloproteinases-1 (TIMP-1) levels also show
predictive potential.
Previously, we reported that in the plasma of blood samples
collected within 96 h from the onset of AP symptoms, the levels of
total MMP-8 predicted AP severity [10]. In the present study we
deliberately restricted the sampling time window to 72 h from the
onset of symptoms in order to unveil whether the markers espe-
cially possess early predictive capacity. While high MMP-8 levels in
our previous study were probably associated with the situation in
which damage has already occurred, now we were able to predic-
tively catch the “danger signs” even earlier. It is also noteworthy
that aMMP-8 determination has been successfully adopted in novel
clinical applications. Regarding inflammatory oral and endocrino-
logical diabetic diseases, analysis technology concerning aMMP-8,
but not total MMP-8, has repeatedly proven to be clinically useful
and functional even at chair-side/point-of-care level, and in the
predictive quantitative on-line and real-time detection of these
inflammatory diseases [17e22]. An intriguing possibility, which
warrants further studies, is whether aMMP-8 testing from oral
fluids could also be applied to AP patients for predicting the
severity of the disease.
While bothMMP-8 andMMP-9 apparently have versatile effects
on inflammatory processes [23], our present and previous [10] re-
sults suggest that MMP-8 appears to bemore considerably involved
in the course of AP. This is supported by several lines of research
including both animal experiments and human studies. First, it has
been demonstrated in mice that MMP-8, and not MMP-9, is crucial
for neutrophil migration through the dense collagenous extracel-
lular matrix by generating collagen-derived chemotactic peptides
during inflammation [24]. Moreover, mice lacking MMP-8 have
been reported to exhibit decreased ventilator-induced lung injury,
attenuated neutrophilic infiltration, lower levels of IFN-g and
chemokines and significant increases in anti-inflammatory cyto-
kines in the lung, whereas there were no differences between
MMP-9 or TIMP-1 knock-out and wild-type mice [25]. We have
reported earlier that in patients with sepsis, serum MMP-8 levels
among non-survivors were significantly higher than among survi-
vors, whereas MMP-9 levels showed no association to mortality
[26]. In another study we found that in patients with burn injury,
plasma MMP-8 levels were higher in those who had large burnt
areas, whereas MMP-9 was not associated with the extent of the
Fig. 4. Serum a) tissue inhibitor of metalloproteinases (TIMP)-1 concentration, b)
activated matrix metalloproteinase (MMP)-8/TIMP-1 molar ratio, and c) MMP-9/TIMP-
1 molar ratio according to the etiology of acute pancreatitis. Post-ERCP pancreatitis in
included in the Other group. Individual measurements are shown overlaid with
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levels and systemic inflammatory conditions (such as sepsis, large
burn injury, or AP), plasma MMP-8 levels have also been associated
with systemic manifestations in metabolic syndrome, whereas
those of MMP-9 have not [28].
Interestingly, and seemingly contradicting our results on MMP-
9, it has been shown in patients with severe traumatic brain injury
that plasma MMP-9 levels are associated with the length of stay at
intensive care unit in those who survive, and also, with mortality
[29]. It is of note that MMP-9 was found to peak between 6 and 12 h
after the trauma. Likewise, in an animal model of multiple organ
dysfunction syndrome (MODS), MMP-9 serum levels peaked early,
12 h from the MODS induction [30]. It is possible that measuring
MMP-9 could be helpful in predicting the development of a severe
disease, but the time window for obtaining reliable results is early
and narrow, and as such, cumbersome to be utilized in practice.
To the best of our knowledge, this is the first time to report that
serum TIMP-1 levels are associated with the etiology of AP. The
reason for the higher TIMP-1 levels in patients with biliary AP
compared to patients with idiopathic or alcohol AP maybe lies in
the differentmechanisms that yet lead to the common outcome, AP.
Biliary pancreatitis is thought to originate when gallstones migrate
out of the gallbladder causing obstruction of the pancreatic duct,
rise in hydrostatic pressure, and subsequently, blockage of
pancreatic secretion and activation of pancreatic enzymes within
the pancreas [31]. Mechanical damage that gallstones potentially
inflict may favor production of profibrogenic factors. Local shift
towards TIMP-1 up-regulation along with bile duct injury has been
described in the context of Schistosoma mansoni -induced liver
fibrosis [32]. Also, in our previous studies we found that serum
TIMP-1 levels of patients with sepsis were significantly higher
among non-survivors than survivors [26], and that plasma TIMP-1
levels of patients with burn injury were associated with the extent
of injury and clinical measures of disease severity as well as 90-day
mortality [27]. The results further suggest that TIMP-1 levels could
indicate the magnitude of cellular stress or damage.
MPO has long been used as a marker of inflammatory neutro-
philic influx, especially in the pancreas and lung in the context of
AP [33]. The current study is one of the first to show an association
between MPO serum levels and development of severe AP. It has
been published newly that circulating MPO levels are associated
with septic shock among critically ill patients, and withmortality in
patients with higher APACHE III scores [34]. MPO plays a well-
known role in promoting oxidative damage during inflammation
by generating hypohalous acids and free radicals. Nowadays it is
also known that hypochlorous acid targets plasmalogens leading to
the production of chlorinated lipids, such as 2-chlorofatty acids (2-
ClFAs). Results from a recent study on septic rats support a role of
free 2-ClFAs as biomarkers of sepsis mortality and endothelial and
epithelial barrier dysfunction [35]. 2-CIFAs also appear capable of
triggering neutrophil extracellular trap (NET) formation, a quite
lately described phenomenon, which is implicated in microcircu-
latory plugging, for example [36]. NET formation has also been
observed in the inflamed pancreas in SAP [37]. Fitting to the results
of these studies, our findings view serum MPO levels as one mea-
sure of tissue damage in patients with AP.
Regarding the associations between aMMP-8 and severity of AP
we report here, one may hypothesize if MMP inhibition could be a
potential approach in order to ameliorate AP. MMPs are chemically
inhibited by tetracycline-group antibiotics, such as doxycycline.horizontal lines denoting medians and boxes denoting 25th to 75th percentiles. The
groups were compared using Kruskal-Wallis test, with statistically significant post hoc
p-values comparing groups shown.
Table 3
Multinomial regression for etiology of AP with biliary etiology as reference category.
Etiology of AP (reference Biliary)
Alcohol Idiopathic Other
Variables in model OR (95% CI) p OR (95% CI) p OR (95% CI) p
Serum TIMP-1 (ng/ml) 0.995 (0.992e0.998) 0.001 0.990 (0.985e0.996) <0.001 0.994 (0.990e0.999) 0.026
Age (years) 0.942 (0.915e0.969) <0.001 0.996 (0.962e1.032) 0.833 0.993 (0.953e1.036) 0.757
Sex (male) 6.776 (2.892e15.879) <0.001 1.475 (0.542e4.019) 0.447 1.774 (0.544e5.779) 0.342
Severity of AP (reference Mild)
Moderately severe 2.120 (0.803e5.601) 0.129 1.032 (0.298e3.578) 0.960 1.468 (0.365e5.913) 0.589
Severe 7.329 (0.983e54.626) 0.052 3.347 (0.197e56.948) 0.404 4.733 (0.286e78.186) 0.277
AP ¼ acute pancreatitis, CI ¼ confidence interval, TIMP ¼ tissue inhibitor of metalloproteinase.
A. Turunen, K. Kuuliala, A. Kuuliala et al. Pancreatology 21 (2021) 862e869However, our previous study showed that in patients with severe
sepsis or septic shock, intravenously received doxycycline has no
impact on MMP-8, -9 or TIMP-1 concentrations or activities [38].
The major concern about doxycycline is probably that cases have
been described in which doxycycline use has induced acute
pancreatitis [39]. Other types of MMP inhibitors have also been
discovered. Results from mouse experiments suggest that while
specific MMP inhibition appears capable of protecting from endo-
toxin shock, finding the correct therapeutical time window can be
challenging [40]. Clearly, future studies are needed to reveal
whether MMP inhibition is a realistic option for treating AP.
Alcohol, and not gallstones (as worldwide), was the main etio-
logical factor for AP in the present study (55.6% and 23.4% of the
patients, respectively). Also, SAP tended to be more common in
patients with alcohol etiology. Although the distribution of alcohol
and biliary etiology reflects well the etiology of acute pancreatitis in
Finland and in some other countries especially in eastern Europe
[2], this should be considered when interpreting the results.
We conclude that serum aMMP-8 levels possess value in pre-
dicting the development of persistent organ dysfunction in AP
patients. Whether the finding can be availed in clinical practice
requires further studies.
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